TriSalus Life Sciences Reports Q3 2026 Revenue of $12.9 Million and Loss of $0. ...
Revenue Rose 11.3% Year-Over-Year as Gross Margin Improved, Though Net Loss Per Share Widened Relative to Analyst Expectations Related Stocks: TLSI ,
Revenue Rose 11.3% Year-Over-Year as Gross Margin Improved, Though Net Loss Per Share Widened Relative to Analyst Expectations Related Stocks: TLSI ,